De primære endpoints var reduktionen af sygdomstegn og symptomer, i henhold til American College of Rheumatology kriterier (ACR20 for ATTRACT, grænsebestemt ACR- N for ASPIRE), forebyggelsen af strukturel ledskade og forbedringen af fysisk funktionsevne.
The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function.